New cell remedy beats immunotherapy in melanoma
Cell therapies have already had a dramatic effect on treating blood cancers, but progress in large tumors has proven more difficult. Now, in a first multicenter randomized trial matching the 2, a new cell remedy has confirmed a superior end result to immunotherapy in patients with upper melanoma.
The cell remedy used in this trial consisted of adoptive tumour-infiltrating lymphocytes (TILs), which were made individually for each affected person, as were chimeric antigen-receiving T cells (CAR T cells) for people with cancers. some blood. However, this is a significantly different method since TILs are produced from lymphocytes that have infiltrated the tumor of the affected person and obtained by surgical intervention within the tumor, whereas CAR T cells are produced from circulating blood cells.
The Part 3 trial involved 168 patients with unresectable stage IIIC-4 melanoma and confirmed that patients treated with TILs achieved significantly improved progression-free survival (PFS) when followed by routine immunotherapy with ipilimumab (Yervoy).
Median PFS more than doubled to 7.2 months with TIL versus 3.1 months with ipilimumab (relative risk [HR]0.50; P
“We believe that TIL could become a new treatment option for patients with advanced-stage melanoma,” commented lead author John Haanen, MD, PhD, research group leader at the Netherlands Institute of Most cancers in Amsterdam and professor of translational immunotherapy. of most cancers at Leiden College Medical Middle in Leiden.
He presented the findings at a presidential symposium as part of the European Society for Medical Oncology (ESMO) Congress 2022 in Paris, France.
“The results of this trial could fuel further analysis of TIL in other types of cancers, arguably demonstrating benefits in many other strong tumors and increasing the treatments available to patients,” said Maya Dimitrova, MD, oncologist. medical at NYU Langone Perlmutter. Middle, metropolis of New York. She was approached for remark by Medscape Medical Information and was not included in the analysis.
Immune checkpoint inhibitors and targeted therapies have become the standard for curing upper melanoma and dramatically improving patient outcomes, she said. However, since about half of the patients treated with these brokers will not get solid benefits, there is still a need to make new choices of remedies.
“Although immunotherapy can yield dramatic long-term responses, a considerable proportion of patients may not respond, or have no robust response, to checkpoint inhibitors,” Dimitrova said. “The TIL remedy has confirmed its effectiveness in melanoma. However, no Part III trials have been completed so far to match its effectiveness with a regular skincare routine.
She noted that these results are in line with previous criticisms of a roughly 50% response price with a strong 20% full response price within the TIL team. Insights from a phase 2 trial reported last year, for example, confirmed an objective response rate of 36.4%.
“Finding out the persistence of antitumor exercise and whether or not there are biomarkers that would help choose the affected person will likely be key given the useful depth of treatment resources,” Dimitrova said. “TIL therapy will apparently become a mainstream new therapy in metastatic melanoma refractory to immune checkpoint inhibitors.”
Superior to immunotherapy
In the current study, Haanen and colleagues randomly assigned 168 patients to either TIL or ipilimumab (3 mg/kg every 3 weeks, most 4 doses). Victims were stratified for BRAFV600 mutation standing, remedy line and middle, and the bulk (86%) were refractory to anti-PD-1 remedy.
Patients in the TIL group underwent resection of a melanoma lesion (2-3 cm) for ex vivo outgrowth and enlargement of tumor-resident T cells. Before the cosmetic TILs were returned to the patients from whom they were made, the affected individual underwent non-myeloablative, lymphodepleting chemotherapy with cyclophosphamide plus fludarabine which was followed by high-dose interleukin-2.
The primary endpoint of the study was progression-free survival and secondary endpoints included total and complete response price, overall survival and safety.
At a median follow-up of 33 months, TIL significantly improved progression-free survival compared to ipilimumab. Overall response price also favored TIL over ipilimumab (49% vs. 21%), with 20% vs. 7% complete responses, respectively.
Median overall survival was 25.8 months for TIL and 18.9 months for ipilimumab (HR, 0.83; P = 0.39).
Adverse treatment-related events of grade 3 or greater occurred in all TILs and 57% of patients with ipilimumab, although Haanen noted that they were manageable and, most often, resolved by the time patients left the hospital.
“There have been no new safety considerations with TIL,” Haanen said, “and these toxicities are pushed by chemotherapy and interleukin-2 that are part of routine TIL. There are no had long-term sequelae in patients treated with TIL and good health-related quality of life was better in patients treated with TIL.
Additionally, commenting on the study, Anthony J. Olszanski, MD, RPh, Affiliate Professor and Vice Chairman of Medical Analytics, Division of Hematology/Oncology at Fox Chase Most Cancers Middle, Philadelphia, Pennsylvania, agreed that the Treatment of patients with melanoma who do not respond or progress after receiving treatment with immunotherapy is “challenging and represents an unmet need”.
“The TIL treatment is, in some ways, an ultra-personalized treatment because we harvest immune cells from the affected person’s tumor, grow them outside the body, and then reinfuse them,” he said. “This trial, which randomized patients between TIL and the CTLA-4 inhibitor ipilimumab, demonstrated powerful progression-free survival and total response cost benefit and may help establish the TIL treatment as a viable treatment technique for some patients.”
The study was supported by the Dutch Society for Most Cancers, the Dutch Group for Health Analysis and Growth, the Dutch Ministry of Health, Stichting Avento, Copenhagen University Hospital, Herlev, the Danish Society of Most Cancers and Denmark’s Capital Analysis Base. .
Haanen and a number of other co-authors said a number of corporate connections were famous in the summary. Olszanski reviews participation on the advisory boards of BMS, Merck, and Instil Bio and he reviews work trials for them.
European Society of Medical Oncology (ESMO) Congress 2022: Abstract LBA3. Offered September 10, 2022.
Roxanne Nelson is an award-winning registered nurse and medical author who has written for many major news outlets and is a daily contributor to Medscape.
To learn more about Medscape Oncology, join us on Twitter and Facebook